

6-7 JULIO 2023

GU-Alliance for Research
and Development

guardsymposium2023

@GuardConsortium

GUARD SYMPOSIUM

Medicina de precisión en cáncer de próstata avanzado

Juan Antonio Vallejo Casas

UGC Medicina Nuclear

Hospital Universitario Reina Sofía

Córdoba


GUARD SYMPOSIUM

6-7 JULIO 2023


GU-Alliance for Research
and Development



guardsymposium2023
@GuardConsortium



Enfermedad avanzada: mCPHS



GUARD SYMPOSIUM

guardsymposium2023
@GuardConsortium


6-7 JULIO 2023



GU-Alliance for Research
and Development

Enfermedad avanzada: redefiniendo nmCPRC

- Estudio retrospectivo multicéntrico
- 200 pacientes nmCPRC
- PSA > 2ng/dl, PSA_{dt} ≥10 m o GS ≥ 8



55% pacientes M₁

GUARD SYMPOSIUM

guardsymposium2023
@GuardConsortium

6-7 JULIO 2023

GU-Alliance for Research
and Development




nmCRPC en imagen convencional

Ca Próstata con M1 en imagen convencional

Elevación postratamiento en mCPRC

Evaluación de respuesta a tratamiento

Selección de pacientes para TRL



GUARD SYMPOSIUM

guardsymposium2023
@GuardConsortium

6-7 JULIO 2023

GU-Alliance for Research
and Development




Selección de pacientes



Diagnóstico
inicial

Tiempo desde
diagnóstico



Historia Terapia

QT status




Test Laboratorio

LDH
F Alcalina
Hemoglobina



Situación clínica

ECOG



PSMA PET/CT

Ganglios pélvicos +
Ganglios a distancia +
Metastasis óseas
Metastasis hepáticas
Captación SUV
Alta carga/nº lesiones
Lesiones PSMA -

GUARD SYMPOSIUM

guardsymposium2023
@GuardConsortium

6-7 JULIO 2023



GU-Alliance for Research and Development


VISION trial

Eligible patients

- Previous treatment with both
 - ≥ 1 androgen receptor pathway inhibitor
 - 1 or 2 taxane regimens
- Protocol-permitted standard of care (SOC) planned before randomization
 - Excluding chemotherapy immunotherapy, radium-223, investigational drugs
- ECOG performance status 0–2
- Life expectancy > 6 months
- PSMA-positive mCRPC on PET/CT with ⁶⁸Ga-PSMA-11





- Randomization stratified by
 - ECOG status (0–1 or 2)
 - LDH (high or low)
 - Liver metastases (yes or no)
 - Androgen receptor pathway inhibitors in SOC (yes or no)
- CT/MRI/bone scans
 - Every 8 weeks (treatment)
 - Every 12 weeks (follow-up)
 - Blinded independent central review



Primary analysis

All randomized patients (N = 831)



GUARD SYMPOSIUM



6-7 JULIO 2023





GU-Alliance for Research and Development

guardsymposium2023
@GuardConsortium

TheraP



177Lu-PSMA-617: 29% (95% CI 16%-42%; p<0.0001) greater PSA50-RR



Number at risk	0	3	6	9	12	15	18
Cabazitaxel	101	46	31	14	2	1	0
Lu-PSMA	99	67	38	28	17	11	4

GUARD SYMPOSIUM

6-7 JULIO 2023




GU-Alliance for Research and Development


guardsymposium2023
@GuardConsortium

LuPARP: Phase 1 trial of ¹⁷⁷Lu-PSMA-617 and olaparib in patients with metastatic castration resistant prostate cancer.

LuPARP: Phase 1 Trial Schema



LuPARP results: PSA Response



- Bien tolerado
- 66% reducción PSA